WaveImplant announces the closing of a first pre-seed round of 170k€

Nantes, France: December 9th, 2020

Thanks to different investors belonging to the industrial network of its founders, WaveImplant, an innovating Medtech start-up created one and a half year ago, succeeded in a first significant capital increase.

 

In order to develop and commercialize ImplantUS by the end of 2023, following their development and financing plan, WaveImplant and its founders (i.e. Guillaume Haïat and Pascal Breton) have mobilized some of their industrial contacts, allowing the closing of a first capital increase of 170k€.  This first reinforcement of the company’s equity allows to continue the pre-industrialisation work of ImplantUS and to initiate the conception design of the pilot device.

Pascal Breton, CEO of WaveImplant, declares: “We are happy to broaden our shareholding with the arrival of seasoned industrials renowned in the fields of healthcare, medical devices, and strategic consulting.  Their trust endorses our entrepreneurial initiative and encourages us to accelerate the development of WaveImplant and increase its visibility among various actors in our field”.

WaveImplant, a French Medtech startup company specialized in the development and commercialization of decision-support medical devices, especially in the field of dental implantology, is focusing on the development of ImplantUS, a new ultrasound-based medical device emerging from the academic research work of Guillaume Haïat’s team within the Laboratoire Modélisation et Simulation Multi-Échelle (MSME, UMR CNRS 8208, Créteil, France).  ImplantUS allows a better control of surgical procedures in dental implantology, which are more and more common, and offers a better guarantee of success on the short and middle term.

The worldwide dental implantology market is very attractive and currently weights €6.0 billion, with a sustained annual growth of 8%.  However, 10 to 20% of all dental implantology procedures still lead to a failure which is highly detrimental for patients and dental surgeons.  In most cases, these failures are the consequence of an insufficient osseointegration of the implant, and of its lack of stability.  Thus, before loading the implant with the prosthesis, practitioners are looking for a reliable and precise estimate of implant stability.  However, the empirical and technological approaches currently available do not bring a satisfying solution and leave a clearly unmet need that ImplantUS is to address.

WAVEIMPLANT

PRODUCTS

MORE

ADDRESS

Headquarters:

12 avenue Carnot

44000 Nantes

France

Laboratories:

61 Avenue du Général de Gaulle

94000 Créteil

France

© 2020 WaveImplant